How We Work

Visterra

Back

Print

CHALLENGE

There is a significant need for new tools to develop vaccine candidates. Currently there is a limited tool set for rational drug and vaccine design.

PROGRAM STRATEGY

The foundation is committed to researching new vaccines for a number of infectious diseases that disproportionately impact individuals living in developing countries. New tools are needed to identify new antigens and epitopes for vaccine candidates

PARTNER

Visterra
Early-stage company with recent technology transfer from Ram Sasisekharan’s lab at MIT

Foundation focus: Protein network mapping technology that could help identify new opportunities

INVESTMENT

Series A Preferred Equity
Date: September 2012
Co-Investors: Flagship Ventures, Polaris
Ventures and Lux Capital
Associated funding: none

Visit Our Blog

Connect